The efficacy of rituximab in the therapy of neuromyelitis optica in a patient with Sjogren's syndrome: case-report and literature review


Cite item

Full Text

Abstract

This case is the first description of the successful anti-B-cell therapy with rituximab in a patient with Sjogrenʼs syndrome and neuromyelitis optica spectrum disorder in Russia. This article contains the literature data on clinical manifestations and methods of the diagnosis of neuromyelitis optica spectrum disorder. Furthermore, contemporary view on the pathogenesis of the combination of this disease with Sjogrenʼs syndrome are presented here.

About the authors

A V Torgashina

V.A. Nasonova Research Institute of Rheumatology

Email: anna.torgashina@gmail.com
к.м.н., м.н.с. лаб. интенсивной терапии ревматических заболеваний Moscow, Russia

V I Vasilyev

V.A. Nasonova Research Institute of Rheumatology

д.м.н., в.н.с. лаб. интенсивной терапии ревматических заболеваний Moscow, Russia

References

  1. Васильев В.И., Грачев Ю.В., Никитин С.С. Поражение периферической и центральной нервной системы при болезни Шегрена. Клинические и теоретические аспекты боли. М.: Издательство РУДН, 2001
  2. Chai J, Logigian E.L. Neurological manifestations of primary Sjögren’s syndrome. Curr Opin Neurol. 2010; 23: 509-13. http://doi.org/10. 1097/WCO.0b013e32833de6ab
  3. Сафонова Т.Н., Васильев В.И., Лихванцева В.Г. Синдром Шегрена: руководство для врачей. М.: Издательство Московского университета; 2013.
  4. Massara A, Bonazza S, Castellino G et al. Central nervous system involvement in Sjogren’s syndrome: Unusual, but not unremarkable - clinical, serological characteristics and outcomes in a large cohort of Italian patients. Rheumatology. 2010; 49(8): 1540-1549. https://doi.org/10.1093/rheumatology/keq111
  5. Vincent T.L, Richardson M.P, Mackworth-Young C.G, Hawke, Venables P.J.W. Sjogren’s syndrome - associated myelopathy: response to immunosuppressive treatment. Am J Med. 2003; 114:145-8. https://doi.org/10.1016/S0002-9343(02)01380-3
  6. Wingerchuk D.M, Lennon V.A, Pittock S.J, Lucchinetti C.F and Weinshenker B.G. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006; 66: 1485-1489. http://doi.org/10.1212/01.wnl. 0000216139. 44259.74
  7. Akaishi T, Nakashima I. Neuromyelitis Optica Spectrum Disorders. Neuroimaging Clin N Am. 2017 May; 27(2): 251-265. http://doi.org/ 10.1016/j.nic.2016.12.010
  8. Lennon V.A, Wingerchuck D.M, Kryzer T.J et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004; 364: 2106-2112. http://doi.org/10.1016/S0140-6736(04) 17551-X
  9. Min J.H, Kim H.J, Kim B.J et al. Brain abnormalities in Sjogren syndrome with recurrent CNS manifestations: association with neuromyelitis optica. Mult Scler. 2009; 15:1069-1076. https://doi.org/ 10.1177/1352458509106228
  10. Wingerchuk D.M, Weinshenker B.G. The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Multiple Sclerosis J. 2012; 18(1): 5-10. https://doi.org/10. 1177/1352458511431077
  11. Wandinger K.P, Stangel M, Witte T, Venables P, Charles P, Jarius S et al. Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjogren ’ s syndrome. Arthritis Rheum. 2010; 62(4):1198-200. https://doi.org/ 10.1002/ art.27337
  12. Wingerchuk D.M, Weinshenker B.G. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology. 2003; 60(5):848-53. https://doi.org/10.1212/01.WNL.0000049912.02954.2C
  13. Ананьева Л.П., Соловьев С.К., Бекетова Т.В., Васильев В.И., Антелава О.А., Александрова Е.Н., Конева О.А., Цанян М.Э., Десинова О.В., Логвиненко О.А., Волков А.В., Хелковская-Сергеева А.Н., Новиков А.А., Алексанкин А.А., Насонов Е.Л. Анти-В-клеточная терапия при иммуновоспалительных ревматических заболеваниях: эффективность и переносимость у 229 больных. Научно - практическая ревматология. 2014; 52(5):495-506. https://doi.org/10. 14412/1995-4484-2014-495-506
  14. Jahnke K, Thiel E. Treatment options for central nervous system lymphomas in immunocompetent patients. Expert Rev Neurother. 2009 Oct;9(10):1497-509. https://doi.org/10.1586/ern.09.100
  15. Batchelor T, Grossman S, Mikkelsen T, Ye X, Desideri S, Lesser G. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology. 2011; 76:929-930. http://doi.org/10. 1212/WNL.0b013e31820f2d94
  16. Carvalho D.C, Tironi T.S, Freitas D.S. Sjögren syndrome and neuromyelitis optica spectrumdisorder co - exist in a common autoimmune milieu. Arq Neuropsiquiatr. 2014 Aug; 72(8):619-24. http://doi.org/10. 1590/0004-282X20140097
  17. Javed A, Balabanov R, Arnason B.G. Minor salivary gland inflammation in Devic’s disease and longitudinally extensive myelitis. Mult Scler. 2008; 14:809-814. https://doi.org/10.1177/1352458508088941
  18. Delporte C, Steinfeld S. Distribution and roles of aquaporins in salivary glands. Biochim Biophys Acta. 2006; 1758:1061-1070. https://doi.org/10.1016/j.bbamem.2006.01.022
  19. Sawada J, Orimoto R et al. A case of pathology - proven neuromyelitis optica spectrum disorder with Sjögren syndrome manifesting aphasia and apraxia due to a localized cerebral white matter lesion. Multiple Sclerosis Journal. 2014; 20(10):1413-1416. https://doi.org/10. 1177/1352458514540834
  20. Kim S.M, Waters P, Vincent A et al. Sjögren’s syndrome myelopathy: spinal cord involvement in Sjögren’s syndrome might be a manifestation of neuromyelitis optica. Mult Scler. 2009; 15:1062-8. https://doi.org/10.1177/1352458509106636
  21. Sellner J, Boggild M, Clanet M et al. EFNS guidelines on the diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010; 17: 1019-1032. https://doi.org/10.1111/j.1468-1331.2010.03066.x
  22. Radaelli M, Moiola L, Sangalli F, Esposito F, Barcella V, Ferre L et al. Neuromyelitis optica spectrum disorders: long - term safety and efficacy of rituximab in Caucasian patients. Mult Scler. 2016 Apr; 22(4):511-9. https://doi.org/10.1177/1352458515594042
  23. Zephir H, Bernard-Valnet R, Lebrun C, Outteryck O, Audoin B, Bourre B et al. Rituximab as first - line therapy in neuromyelitis optica: efficiency and tolerability. J Neurol. 2015; 262: 2329-2335. https://doi.org/10.1007/s00415-015-7852-y
  24. Kim S, Kim W, Li X, Jung I and Kim H. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. 2011; 68: 1412-1420. https://doi.org/10.1001/archneurol.2011. 154
  25. Mealy M, Wingerchuk D, Palace J, Greenberg B and Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014; 71: 324-330. https://doi.org/10.1001/jamaneurol.2013.5699
  26. Ramakrishna R, Chaudhuri K, Sturgess A, Manoharan A. 1992 Haematological manifestations of primary Sjogren’s syndrome: a clinicopathological study. Q J Med. 1992; 83:547-54. https://doi.org/ 10.1016/S0031-3025(16)35939-6
  27. Capsoni F, Sarzi-Puttini P, Zanella A. Primary and secondary autoimmune neutropenia. Arthritis Res Ther. 2005; 7:208-14. https://doi.org/ 10.1186/ar1803
  28. Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F. Delayed - onset neutropenia associated with rituximab therapy. Br J Haematol. 2003; 121(6):913-8. https://doi.org/10.1046/j.1365-2141.2003.04385.x
  29. Dunleavy K, Hakim F, Kim H.K, Janik J.E, Grant N, Nakayama T, White T, Wright G, Kwak L, Gress R, Tosato G, Wilson W.H. B-cell recovery following rituximab - based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood. 2005; 106(3):795-802. https://doi.org/10.1182/blood-2004-08-3198

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies